This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
ipeptidyl peptidase IV (DPP-IV) is an enzyme of considerable biomedical interest.
It plays an important role in glucose homeostasis through proteolytic inactivation
of incretin hormones, primarily glucagon like peptide-1 (GLP-1) which is critical in
sugar balance. Traditionally, the DPP-IV inhibitors were evaluated using fl
or chromogenic methods. However, it is limited by the selection of substrates since the
cleavage product of the substrates must be fl
uorogenic or chromogenic. In addition, it
requires that the candidate inhibitors should be of no fl
uorescence or chromophorous.
Professor Lei Fu received his Ph.D. degree in Chemistry from Stanford University. After a one-year
postdoctoral research at Stanford, he joined Pharmacyclics Inc., California in 1998, conducting drug
discovery and development research on anti-cancer and anti-cardiovascular diseases. Dr. Fu has been
a Professor of Medicinal Chemistry at Shanghai Jiao Tong University since 2006. His principal research
interests are 1) drug discovery and development; 2) traditional Chinese Medicines as botanical
cosmeceuticals; 3) medical devices as targeted drug delivery systems and 4) chemical induction of
hypothermia. He was a visiting scholar in the Department of Chemistry, Stanford University in 2009.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals